Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6

Hepatology. 2007 Jan;45(1):258-9. doi: 10.1002/hep.21505.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Clinical Trials as Topic
  • Drug Therapy, Combination
  • Europe
  • Follow-Up Studies
  • Genotype
  • Hepacivirus / drug effects
  • Hepacivirus / genetics*
  • Hepatitis C / blood
  • Hepatitis C / drug therapy*
  • Hepatitis C / genetics
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / pharmacology
  • Interferon-alpha / therapeutic use*
  • Multicenter Studies as Topic
  • Polyethylene Glycols / pharmacology
  • Polyethylene Glycols / therapeutic use*
  • Predictive Value of Tests
  • RNA, Viral / blood*
  • Recombinant Proteins
  • Ribavirin / pharmacology
  • Ribavirin / therapeutic use*
  • Treatment Outcome
  • Viral Load

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a